NVIDIA (NASDAQ:NVDA): Why its a Strong and Undervalued Buy
07 Mar

NVIDIA (NASDAQ:NVDA): Why its a Strong and Undervalued Buy

NVIDIA Corporation (NASDAQ:NVDA) has experienced tremendous growth, with its net income surging 144.89% year-over-year (YoY), driven by high demand for AI and data center GPUs. Despite this, NVDA stock has declined over 20% year-to-date (YTD), entering a bear market. However, this presents an opportunity for long-term investors as major tech…
Read Full
Federal Reserve Holds Rates Amid Trump’s Policy Uncertainty
07 Mar

Federal Reserve Holds Rates Amid Trump’s Policy Uncertainty

Powell Reaffirms Patient Stance on Interest Rates Federal Reserve Chairman Jerome Powell stated on Friday that the central bank remains in a wait-and-see mode before making further interest rate adjustments. Speaking at the U.S. Monetary Policy Forum in New York, Powell emphasized that the Federal Reserve (Fed) holds rates steady…
Read Full
Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation
06 Mar

Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation

Plus Therapeutics Gains with FDA Orphan Drug Designation Plus Therapeutics (PSTV) Gains 311% with FDA Orphan Drug Designation, Plus Therapeutics a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics, has seen its stock skyrocket by +311.43%. This impressive surge follows the U.S. Food and Drug Administration's (FDA) decision to grant Orphan…
Read Full
Like Us
Follow Us
Subscribe Us
Follow Us
×